Peripheral Arterial Occlusive Disease (PAOD)

Current Situation

Patients suffering from peripheral arterial occlusive disease have narrowing or occlusion of the peripheral arteries, leading to decreased blood flow in the (mostly lower) extremities. The main cause is atherosclerosis and symptoms include coldness, numbness, pain and chronic wounds, such as ulcers. 5-10% of patients with PAOD will undergo amputation.



To perform in vivo and in vitro investigations of the effects that ABCB5+ cells have on neovascularization, with the aim of eventually using these cells in stem cell based drug development.



Since the beginning of 2015 pre-clinical studies are conducted to analyze the mode of action of ABCB5+ cells. Cell performance under oxygen-deficient conditions are investigated.

All safety studies on the safety and efficacy of ABCB5+ cells in the model have been successfully completed.

Clinical studies with allogeneic ABCB5+ cells in patients with peripheral arterial occlusive disease are planned for late August 2017.




« back


Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

Clinical Trial

Together with our subsidiary RHEACELL we are recruiting patients with the indication chronic venous ulcer (CVU) for the clinical trial in phase 1/2a. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.